Clinical trials: Drug
Clostridium Difficile Infection
Effect of Acid Suppression Medication on Pediatric Microbiome
The colonic microbiome is essential in health and disease, and is highly dynamic during the first several years of life. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely used in children, but…
- Trial name
- NCT02016820
- Testing
- Omeprazole (suspension), Lifestyle Modification
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Diabetes, Diabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes.
- Trial name
- DUAL™ I (NCT01336023)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,663 people
- Sponsor
- Novo Nordisk A/S
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
Anal Human Papillomavirus in Inflammatory Bowel Disease Study
This is an observational cohort study with two time points (baseline and after at least 6 months of treatment with a non-corticosteroid immunosuppressive agent for inflammatory bowel disease (IBD)).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
- Trial name
- AnalHPV&IBD (NCT01364896)
- Testing
- Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Pittsburgh
Hypertension
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
The purpose of this study is to gain an understanding of the actual use of candesartan cilexetil (Blopress) in patients with hypertension, and to examine the changes in parameters such as blood pressure.
- Trial name
- NCT02211638
- Testing
- Candesartan Cilexetil
- Where
- Japan
- Volunteers
- 18,113 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
- Trial name
- NCT00286455
- Testing
- Alogliptin
- Where
- 67 sites in United States, Argentina and 16 more
- Volunteers
- 329 people
- Sponsor
- Takeda
Lung Cancer
Phase 2 Study of VGT-309 in Lung Cancer
A Phase 2 open label study to evaluate safety and efficacy of VGT-309 to identify cancer in up to 40 subjects undergoing lung cancer surgery.
- Trial name
- NCT05400226
- Testing
- VGT-309
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vergent Bioscience, Inc.
Osteoarthritis, Rheumatoid Arthritis
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome
- Trial name
- NCT00984815
- Testing
- HZT-501
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Amgen
Solid Tumors
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or…
- Trial name
- NCT02598960
- Testing
- BMS-986156, Nivolumab
- Where
- 27 sites in United States, Australia and 8 more
- Volunteers
- 295 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Hypersensitivity
Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever.
- Trial name
- NCT01569191
- Testing
- Artificial Tear Supplement, Cold compress, Anti-allergic Medication
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Aston University
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Heart Disease, Lung Disease
Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)
This is a pilot study that seeks to evaluate the feasibility and safety of using a TEG algorithm in addition to traditional laboratory tests to guide transfusion and coagulation management of ECMO patients.
- Trial name
- NCT02887820
- Testing
- Thromboelastograph
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stephen Esper
Myopia and Hyperopia and Presbyopia
Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens
The objective of this study is to evaluate the product performance of a new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens, when worn by…
- Trial name
- NCT05660577
- Testing
- new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
- Where
- 20 sites in United States
- Volunteers
- 301 people
- Sponsor
- Bausch & Lomb Incorporated
Healthy Volunteers
Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germany (TOB) relative to that of…
- Trial name
- NCT03131895
- Testing
- 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Takeda
Pregnancy Preterm, Neonatal Hypoglycemia
Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study
Annually in the U.S 300,000 neonates are born late preterm, defined as 34 weeks 0 days - 36 weeks 6 days. The Antenatal Late Preterm Steroids (ALPS) Trial demonstrated that maternal treatment with betamethasone in the late…
- Conditions
- Pregnancy Preterm, Neonatal Hypoglycemia, Hyperglycemia Drug Induced
- Trial name
- E-ALPS (NCT03076775)
- Testing
- Maternal glycemic control
- Where
- 2 sites in United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Prostate Cancer
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC)…
- Trial name
- NCT03148795
- Testing
- Talazoparib
- Where
- 120 sites in United States, Australia and 12 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Cognitive Impairment
An Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia
The aim of this randomized controlled study is to investigate if medication reviews performed by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce readmissions to hospital among elderly…
- Trial name
- NCT01504672
- Testing
- Medication review
- Where
- 2 sites in Sweden
- Volunteers
- 460 people
- Sponsor
- Umeå University
Cholera
Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
The primary objective of this study is to evaluate the antibody response to the cholera vaccine, Vaxchora®, in healthy subjects.
- Trial name
- NCT03251495
- Testing
- Vaxchora
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Emory University
Asthma
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in…
- Trial name
- NCT06261957
- Testing
- Salbutamol HFA-134a, Salbutamol HFA-152a
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 471 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic, Substance Abuse, Intravenous
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling.
- Trial name
- SUPPORT (NCT00726557)
- Testing
- PegIntron (pegylated interferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.